CLINICAL TRIALS AND OBSERVATIONS

Targeted Agents for Chronic Myelogenous Leukemia: Will That Be the End of Allogeneic Bone Marrow Transplantation for That Disease?

Liang, Yuzhen
Lai, Yongrong
Schwarzenberger, Paul
Li, Qiaochuan
Ma, Jie
Luo, Jun
Liu, Rongrong
Shi, Lingling
Zhou, Jicheng
Peng, Zhigang
Yang, Jie
Deng, Donghong
Zhou, Yizhen

June 2010

Although the drug imatinib has been accepted as the treatment of choice for chronic myelogenous leuk...

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: A phase 2 trial of the GIMEMA CML Working Party

Castagnetti, Fausto
Palandri, Francesca
Amabile, Marilina
Testoni, Nicoletta
Luatti, Simona
Soverini, Simona
Iacobucci, Ilaria
Breccia, Massimo
Cambrin, Giovanna Rege
Stagno, Fabio
Specchia, Giorgina
Galieni, Piero
Iuliano, Franco
Pane, Fabrizio
Saglio, Giuseppe
Alimena, Giuliana
Martinelli, Giovanni
Baccarani, Michele
Rosti, Gianantonio
GIMEMA CML Working Party
BOCCHIA, MONICA

January 2009

Imatinib mesylate has become the treatment of choice for chronic myeloid leukemia (CML): the standar...

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: A phase 2 trial of the GIMEMA CML Working Party

Castagnetti, Fausto
Palandri, Francesca
Amabile, Marilina
Testoni, Nicoletta
Luatti, Simona
Soverini, Simona
Iacobucci, Ilaria
Breccia, Massimo
Cambrin, Giovanna Rege
Stagno, Fabio
Specchia, Giorgina
Galieni, Piero
Iuliano, Franco
Pane, Fabrizio
Saglio, Giuseppe
Alimena, Giuliana
Martinelli, Giovanni
Baccarani, Michele
Rosti, Gianantonio
GIMEMA CML Working Party
BOCCHIA, MONICA

January 2009

Imatinib mesylate has become the treatment of choice for chronic myeloid leukemia (CML): the standar...

Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase

Jiang, Qian
Xu, Lan-Ping
Liu, Dai-Hong
Liu, Kai-Yan
Chen, Shan-Shan
Jiang, Bin
Jiang, Hao
Chen, Huan
Chen, Yu-Hong
Han, Wei
Zhang, Xiao-Hui
Wang, Yu
Qin, Ya-Zhen
Liu, Yan-Rong
Lai, Yue-Yun
Huang, Xiao-Jun

January 2011

The relative merits of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and imatinib f...

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era : evaluation of its impact within a subgroup of the randomized German CML Study IV

Saussele, Susanne
Lauseker, Michael
Gratwohl, Alois
Beelen, Dietrich W.
Bunjes, Donald
Schwerdtfeger, Rainer
Kolb, Hans-Jochem
Ho Anthony, D.
Falge, Christiane
Holler, Ernst
Schlimok, Günter
Zander, Axel R.
Arnold, Renate
Kanz, Lothar
Dengler, Robert
Haferlach, Claudia
Schlegelberger, Brigitte
Pfirrmann, Markus
Müller, Martin C.
Schnittger, Susanne
Leitner, Armin
Pletsch, Nadine
Hochhaus, Andreas
Hasford, Joerg
Hehlmann, Rüdiger
German CML Study Group,

January 2010

The role of allogeneic stem cell transplantation in chronic myeloid leukemia is being reevaluated. W...

TRANSPLANTATION

Mary M. Horowitz
Richard T. Maziarz

October 2016

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic m...

Imatinib as a Dominant Therapeutic Strategy in the Treatment of Chronic Myelogenous Leukemia: A Decision-Analytic Approach

Ballard, Erin Elissa

January 2004

Class of 2004 AbstractObjective: To develop and populate a decision-analytic model comparing the cos...

Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia

Deenik, W.
Janssen, J.J.W.M.
Holt, B. van der
Verhoef, G.E.G.
Smit, W.M.
Kersten, M.J.
Daenen, S.M.G.J.
Verdouck, L.F.
Ferrant, A.
Schattenberg, A.V.M.B.
Sonneveld, P.
Kooy, M.V.
Wittebol, S.
Willemze, R.
Wijermans, P.W.
Beverloo, H.B.
Lowenberg, B.
Valk, P.J.M.
Ossenkoppele, G.J.
Cornelissen, J.J.

June 2010

Immunobiology of allogeneic stem cell transplantation and immunotherapy of hematological disease

Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias

TIRIBELLI, M
MARIN L
CALISTRI E
GEROMIN A
DAMIANI, D
FANIN,R

January 2004

Imatinib mesylate is extremely active in Philadelphia-positive (Ph+) chronic myeloid leukaemia (CML)...

Imatinib mesylate in the treatment of chronic myeloid leukemia: a local experience

Bee, P.C.
Gan, G.G.
Teh, A.
Haris, A.R.

January 2006

This study was done to assess the overall response rate of imatinib mesylate in local patients with ...

Hematologic and cytogenetic findings in eleven chronic myelogenous leukemia patients treated with imatinib mesylate at a tertiary care hospital

Usman, M.
Kakepoto, G. N.
Adil, Salman
Sajid, R.
Arain, S.
Khurshid, Mohammad

January 2004

Objective: To evaluate the response of Imatinib mesylate in patients with myeloid leukemi...

Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors - A synthesis of clinical and laboratory data

Irvine, D. A.
Heaney, N. B.
Holyoake, T. L.

January 2010

The introduction of imatinib, a tyrosine kinase inhibitor (TKI) that targets the BCR-ABL protein, ha...

Hematologic and cytogenetic findings in eleven chronic myelogenous leukemia patients treated with imatinib mesylate at a tertiary care hospital

Usman, M.
Kakepoto, G. N.
Adil, Salman
Sajid, R.
Arain, S.
Khurshid, Mohammad

January 2004

Objective: To evaluate the response of Imatinib mesylate in patients with myeloid leukemi...

Targeted Agents for Chronic Myelogenous Leukemia: Will That Be the End of Allogeneic Bone Marrow Transplantation for That Disease?

Liang, Yuzhen
Lai, Yongrong
Schwarzenberger, Paul
Li, Qiaochuan
Ma, Jie
Luo, Jun
Liu, Rongrong
Shi, Lingling
Zhou, Jicheng
Peng, Zhigang
Yang, Jie
Deng, Donghong
Zhou, Yizhen

June 2010

Although the drug imatinib has been accepted as the treatment of choice for chronic myelogenous leuk...

| 232 | haematologica/the hematology journal | 2005; 90(2)

Carmino Antonio
De Souza
Afonso Celso Vigorito
Milton Artur Ruiz
Márcio Nucci
Frederico Luiz Dulley
Vaneusa Funcke
Daniel Tabak
Alexandre Mello Azevedo
Rita Byington
Maria Cristina Macedo
Rosaura Saboya
Francisco José
Penteado Aranha
Gislaine Barbosa Oliveira
Roberto Zulli
Eliana Cristina
Martins Miranda
Wellington Moraes Azevedo
Fernanda Maria Lodi
Júlio Cesar Voltarelli
Belinda Pinto Simões
Vergílio Colturato
Mair Pedro
De Souza
Lúcia Silla
Henrique Bittencourt
Lilian Piron-ruiz
Angelo Maiolino
Alois Gratwohl
Ricardo Pasquini

December 2014

Validation of the EBMT risk score in chronic myeloid leukemia in Brazil and allogeneic transplant ou...

Targeted Agents for Chronic Myelogenous Leukemia: Will That Be the End of Allogeneic Bone Marrow Transplantation for That Disease?

Liang, Yuzhen
Lai, Yongrong
Schwarzenberger, Paul
Li, Qiaochuan
Ma, Jie
Luo, Jun
Liu, Rongrong
Shi, Lingling
Zhou, Jicheng
Peng, Zhigang
Yang, Jie
Deng, Donghong
Zhou, Yizhen

June 2010

Although the drug imatinib has been accepted as the treatment of choice for chronic myelogenous leuk...

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: A phase 2 trial of the GIMEMA CML Working Party

Castagnetti, Fausto
Palandri, Francesca
Amabile, Marilina
Testoni, Nicoletta
Luatti, Simona
Soverini, Simona
Iacobucci, Ilaria
Breccia, Massimo
Cambrin, Giovanna Rege
Stagno, Fabio
Specchia, Giorgina
Galieni, Piero
Iuliano, Franco
Pane, Fabrizio
Saglio, Giuseppe
Alimena, Giuliana
Martinelli, Giovanni
Baccarani, Michele
Rosti, Gianantonio
GIMEMA CML Working Party
BOCCHIA, MONICA

January 2009

Imatinib mesylate has become the treatment of choice for chronic myeloid leukemia (CML): the standar...

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: A phase 2 trial of the GIMEMA CML Working Party

Castagnetti, Fausto
Palandri, Francesca
Amabile, Marilina
Testoni, Nicoletta
Luatti, Simona
Soverini, Simona
Iacobucci, Ilaria
Breccia, Massimo
Cambrin, Giovanna Rege
Stagno, Fabio
Specchia, Giorgina
Galieni, Piero
Iuliano, Franco
Pane, Fabrizio
Saglio, Giuseppe
Alimena, Giuliana
Martinelli, Giovanni
Baccarani, Michele
Rosti, Gianantonio
GIMEMA CML Working Party
BOCCHIA, MONICA

January 2009

Imatinib mesylate has become the treatment of choice for chronic myeloid leukemia (CML): the standar...

Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase

Jiang, Qian
Xu, Lan-Ping
Liu, Dai-Hong
Liu, Kai-Yan
Chen, Shan-Shan
Jiang, Bin
Jiang, Hao
Chen, Huan
Chen, Yu-Hong
Han, Wei
Zhang, Xiao-Hui
Wang, Yu
Qin, Ya-Zhen
Liu, Yan-Rong
Lai, Yue-Yun
Huang, Xiao-Jun

January 2011

The relative merits of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and imatinib f...

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era : evaluation of its impact within a subgroup of the randomized German CML Study IV

Saussele, Susanne
Lauseker, Michael
Gratwohl, Alois
Beelen, Dietrich W.
Bunjes, Donald
Schwerdtfeger, Rainer
Kolb, Hans-Jochem
Ho Anthony, D.
Falge, Christiane
Holler, Ernst
Schlimok, Günter
Zander, Axel R.
Arnold, Renate
Kanz, Lothar
Dengler, Robert
Haferlach, Claudia
Schlegelberger, Brigitte
Pfirrmann, Markus
Müller, Martin C.
Schnittger, Susanne
Leitner, Armin
Pletsch, Nadine
Hochhaus, Andreas
Hasford, Joerg
Hehlmann, Rüdiger
German CML Study Group,

January 2010

The role of allogeneic stem cell transplantation in chronic myeloid leukemia is being reevaluated. W...

TRANSPLANTATION

Mary M. Horowitz
Richard T. Maziarz

October 2016

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic m...

Imatinib as a Dominant Therapeutic Strategy in the Treatment of Chronic Myelogenous Leukemia: A Decision-Analytic Approach

Ballard, Erin Elissa

January 2004

Class of 2004 AbstractObjective: To develop and populate a decision-analytic model comparing the cos...

Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia

Deenik, W.
Janssen, J.J.W.M.
Holt, B. van der
Verhoef, G.E.G.
Smit, W.M.
Kersten, M.J.
Daenen, S.M.G.J.
Verdouck, L.F.
Ferrant, A.
Schattenberg, A.V.M.B.
Sonneveld, P.
Kooy, M.V.
Wittebol, S.
Willemze, R.
Wijermans, P.W.
Beverloo, H.B.
Lowenberg, B.
Valk, P.J.M.
Ossenkoppele, G.J.
Cornelissen, J.J.

June 2010

Immunobiology of allogeneic stem cell transplantation and immunotherapy of hematological disease

Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias

TIRIBELLI, M
MARIN L
CALISTRI E
GEROMIN A
DAMIANI, D
FANIN,R

January 2004

Imatinib mesylate is extremely active in Philadelphia-positive (Ph+) chronic myeloid leukaemia (CML)...

Imatinib mesylate in the treatment of chronic myeloid leukemia: a local experience

Bee, P.C.
Gan, G.G.
Teh, A.
Haris, A.R.

January 2006

This study was done to assess the overall response rate of imatinib mesylate in local patients with ...

Hematologic and cytogenetic findings in eleven chronic myelogenous leukemia patients treated with imatinib mesylate at a tertiary care hospital

Usman, M.
Kakepoto, G. N.
Adil, Salman
Sajid, R.
Arain, S.
Khurshid, Mohammad

January 2004

Objective: To evaluate the response of Imatinib mesylate in patients with myeloid leukemi...

Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors - A synthesis of clinical and laboratory data

Irvine, D. A.
Heaney, N. B.
Holyoake, T. L.

January 2010

The introduction of imatinib, a tyrosine kinase inhibitor (TKI) that targets the BCR-ABL protein, ha...

Hematologic and cytogenetic findings in eleven chronic myelogenous leukemia patients treated with imatinib mesylate at a tertiary care hospital

Usman, M.
Kakepoto, G. N.
Adil, Salman
Sajid, R.
Arain, S.
Khurshid, Mohammad

January 2004

Objective: To evaluate the response of Imatinib mesylate in patients with myeloid leukemi...

Targeted Agents for Chronic Myelogenous Leukemia: Will That Be the End of Allogeneic Bone Marrow Transplantation for That Disease?

Liang, Yuzhen
Lai, Yongrong
Schwarzenberger, Paul
Li, Qiaochuan
Ma, Jie
Luo, Jun
Liu, Rongrong
Shi, Lingling
Zhou, Jicheng
Peng, Zhigang
Yang, Jie
Deng, Donghong
Zhou, Yizhen

June 2010

Although the drug imatinib has been accepted as the treatment of choice for chronic myelogenous leuk...

| 232 | haematologica/the hematology journal | 2005; 90(2)

Carmino Antonio
De Souza
Afonso Celso Vigorito
Milton Artur Ruiz
Márcio Nucci
Frederico Luiz Dulley
Vaneusa Funcke
Daniel Tabak
Alexandre Mello Azevedo
Rita Byington
Maria Cristina Macedo
Rosaura Saboya
Francisco José
Penteado Aranha
Gislaine Barbosa Oliveira
Roberto Zulli
Eliana Cristina
Martins Miranda
Wellington Moraes Azevedo
Fernanda Maria Lodi
Júlio Cesar Voltarelli
Belinda Pinto Simões
Vergílio Colturato
Mair Pedro
De Souza
Lúcia Silla
Henrique Bittencourt
Lilian Piron-ruiz
Angelo Maiolino
Alois Gratwohl
Ricardo Pasquini

December 2014

Validation of the EBMT risk score in chronic myeloid leukemia in Brazil and allogeneic transplant ou...

Targeted Agents for Chronic Myelogenous Leukemia: Will That Be the End of Allogeneic Bone Marrow Transplantation for That Disease?

Liang, Yuzhen
Lai, Yongrong
Schwarzenberger, Paul
Li, Qiaochuan
Ma, Jie
Luo, Jun
Liu, Rongrong
Shi, Lingling
Zhou, Jicheng
Peng, Zhigang
Yang, Jie
Deng, Donghong
Zhou, Yizhen

June 2010

Although the drug imatinib has been accepted as the treatment of choice for chronic myelogenous leuk...

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: A phase 2 trial of the GIMEMA CML Working Party

Castagnetti, Fausto
Palandri, Francesca
Amabile, Marilina
Testoni, Nicoletta
Luatti, Simona
Soverini, Simona
Iacobucci, Ilaria
Breccia, Massimo
Cambrin, Giovanna Rege
Stagno, Fabio
Specchia, Giorgina
Galieni, Piero
Iuliano, Franco
Pane, Fabrizio
Saglio, Giuseppe
Alimena, Giuliana
Martinelli, Giovanni
Baccarani, Michele
Rosti, Gianantonio
GIMEMA CML Working Party
BOCCHIA, MONICA

January 2009

Imatinib mesylate has become the treatment of choice for chronic myeloid leukemia (CML): the standar...

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: A phase 2 trial of the GIMEMA CML Working Party

Castagnetti, Fausto
Palandri, Francesca
Amabile, Marilina
Testoni, Nicoletta
Luatti, Simona
Soverini, Simona
Iacobucci, Ilaria
Breccia, Massimo
Cambrin, Giovanna Rege
Stagno, Fabio
Specchia, Giorgina
Galieni, Piero
Iuliano, Franco
Pane, Fabrizio
Saglio, Giuseppe
Alimena, Giuliana
Martinelli, Giovanni
Baccarani, Michele
Rosti, Gianantonio
GIMEMA CML Working Party
BOCCHIA, MONICA

January 2009

Imatinib mesylate has become the treatment of choice for chronic myeloid leukemia (CML): the standar...

CLINICAL TRIALS AND OBSERVATIONS

Abstract

Extracted data

CLINICAL TRIALS AND OBSERVATIONS

Abstract

Extracted data

Related items

Related items